|By PR Newswire||
|February 13, 2014 11:36 AM EST||
MILLBROOK, N.Y., Feb. 13, 2014 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Emmanuel Petricoin III, Ph.D. to its Board of Directors and Scientific Advisory Committee.
Dr. Emanuel F Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a University Professor. Prior to this position, he served as Co-Director of the FDA-NCI Clinical Proteomics Program from 2001-2005, and a Senior Investigator within the Center for Biologics Evaluation and Research at the US Food and Drug Administration from 1993-2005. Dr. Petricoin received his PhD in Microbiology from the University of Maryland in 1990. The focus of the CAPMM is the invention and use of proteomics technologies for personalized therapy, and biomarker discovery and measurement for direct clinical applications at the bedside. He is a co-founder of 3 life science companies, Theranostics Health, Inc, Ceres Nanosciences Inc., and Perthera, Inc. He is a co-inventor on 40 filed and published patents, and has authored over 300 peer-reviewed publications and invited reviews. He has authored over 40 book chapters, is the Co-Editor-in-Chief of Human Genomics and Proteomics, is on the editorial board of Proteomics, Biomedical Microdevices, Proteomics- Clinical Applications, Proteomics- Protocols, Molecular Carcinogenesis, Journal of Personalized Medicine and is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention. He was the founding Co-Editor-in-Chief of Clinical Proteomics. Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO) as well as the US HUPO and served on the Executive Committee and Treasurer for HUPO from 2002-2004. He is a member of the Faculty of 1000. He has received numerous awards including the University Professorship at George Mason University, the NIH Director's Award, FDA Distinguished Scientist Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award.
Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer's. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated be a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com
SOURCE Egenix, Inc.